News Release

A human factor

Unexpected findings on SARS-CoV-2 replication

Peer-Reviewed Publication

Helmholtz Centre for Infection Research

New findings on SARS-CoV-2


New findings on SARS-CoV-2: Jun Prof Mathias Munschauer with PhD student Sabina Ganskih in the lab.

view more 

Credit: @HIRI/Frédéric Gerth

SARS-CoV-2, the virus responsible for the disease COVID-19 with nearly seven million deaths worldwide to date, has a characteristic genetic makeup made entirely of ribonucleic acid (RNA). This RNA contains instructions for creating new copies of the virus. When SARS-CoV-2 infects a host cell, it takes over the cell's gene expression machinery to copy and reproduce itself. This involves creating various types of viral RNA, each with a specific role in the replication cycle of the virus.

In a study of the Würzburg Helmholtz Institute for RNA-based Infection Research, a site of the Braunschweig Helmholtz Centre for Infection Research in cooperation with the Julius-Maximilians-Universität Würzburg, a team headed by research group leader Mathias Munschauer focused on the interactions between different SARS-CoV-2 RNAs and the proteins of the human host cell. Their findings have just been published in the journal Cell.


“While we have learned a lot about the functions of the virus's own proteins, we are still figuring out how proteins from the infected human cell impact the ability of SARS-CoV-2 to replicate,” Munschauer explains the backdrop of the study.


Nora Schmidt is a postdoc in the Munschauer lab and one of the co-first authors. “We discovered that a host protein called SND1 recognizes a specific type of viral RNA known as negative-sense RNA,” she says. “This negative-sense RNA serves as a template for amplifying new viral RNA molecules, but is not translated into protein.”


Addition to the SARS-CoV-2 textbook

SND1 turned out to be essential for the virus to effectively copy viral RNA within human cells. It not only binds to the negative-sense viral RNA synthesis templates, but also interacts with a viral protein called NSP9.

Yuanjie Wei is also a member of the first authors’ team. “Our research revealed a crucial detail,” the PhD student is happy to report. “Stimulated by the human factor SND1, the virus kickstarts its RNA production by using its own protein NSP9 as a primer.” In other words, NSP9 serves as the first building block of the growing RNA chain.

With SND1, the authors describe the first host protein identified to recognize negative-sense viral RNA. They were also able to show for the first time that the binding of a human protein to SARS-CoV-2 RNA and its interaction with NSP9 is helping to initiate viral replication. If the host factor SND1 is absent, the initiation of viral RNA synthesis by NSP9 is impaired and the production of viral RNA is less efficient.

These findings are surprising and prompt an update of the coronavirus textbooks, concluded the team, which also involved scientists from other research institutions in Germany and the U.S., including the FOR-COVID Research Network and the Broad Institute of MIT and Harvard in Boston. In addition to basic research, medicine could benefit from new therapeutic targets in the future. What’s more, there is evidence that rare sequence variants in the SND1 gene may be linked to severe COVID-19 infections and hospitalizations.

In this context, further research is required. It will also be interesting to analyze in the future if the function of SND1 and NSP9 is conserved in other coronaviruses or, for example, if the human protein SND1 also stimulates replication of other RNA viruses that cause human disease, such as influenza or RSV (respiratory syncytial virus). Moreover, future work will need to illuminate the exact molecular features driving SND1 binding to negative-sense RNA of SARS-CoV-2 or other coronaviruses.

At a glance

  • NSP9 primes SARS-CoV-2 RNA synthesis in human cells – a fundamental new insight into the SARS-CoV-2 RNA synthesis mechanism.
  • SND1 stimulates this protein-priming mechanism by directly interacting with negative-sense viral RNA and the viral protein NSP9.


  • SND1 is required for nascent SARS-CoV-2 RNA synthesis early during infection.


The study was supported by funding from the Helmholtz Young Investigator Group Program, the European Research Council, and the FOR-COVID Research Network. Nora Schmidt was additionally funded through the EMBO Long-term Fellowship Program.


Original Publication


Schmidt N, Ganskih S, Wei Y, Gabel A, Zielinski S, (…) Munschauer M

SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9

Cell (2023), DOI: 


Helmholtz Institute for RNA-based Infection Research

The Helmholtz Institute for RNA-based Infection Research (HIRI) is the first institution of its kind worldwide to combine ribonucleic acid (RNA) research with infection biology. Based on novel findings from its strong basic research program, the institute’s long-term goal is to develop innovative therapeutic approaches to better diagnose and treat human infections.

HIRI is a site of the Braunschweig Helmholtz Centre for Infection Research (HZI) in cooperation with the Julius-Maximilians-Universität Würzburg (JMU) and is located on the Würzburg Medical Campus.

More information at


Media Contact

Dr Britta Grigull

Head of Communications

Helmholtz Institute for RNA-based Infection Research (HIRI)

+49 (0)931 31 81801




Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.